MX2009012453A - Composiciones de amoniaco-liasa de fenilalanina procariotica y metodos de uso de dichas composiciones. - Google Patents

Composiciones de amoniaco-liasa de fenilalanina procariotica y metodos de uso de dichas composiciones.

Info

Publication number
MX2009012453A
MX2009012453A MX2009012453A MX2009012453A MX2009012453A MX 2009012453 A MX2009012453 A MX 2009012453A MX 2009012453 A MX2009012453 A MX 2009012453A MX 2009012453 A MX2009012453 A MX 2009012453A MX 2009012453 A MX2009012453 A MX 2009012453A
Authority
MX
Mexico
Prior art keywords
compositions
pal
lyase
methods
phenylalanine ammonia
Prior art date
Application number
MX2009012453A
Other languages
English (en)
Inventor
Paul A Fitzpatrick
Emil D Kakkis
Michel C Vellard
Daniel J Wendt
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39868905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009012453(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MX2009012453A publication Critical patent/MX2009012453A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención está dirigida a la amoniaco-liasa de fenilalanina (PAL) producida por los procariotes, en que tal PAL procariótica, donde la variante PAL tiene una actividad mayor de conversión de fenilalanina y/o una inmunogenicidad reducida cuando se compara con una PAL de tipo natural. La invención proporciona entonces composiciones de PAL bacteriana y fragmentos, mutantes, variantes y análogos biológicamente activos de la misma, así como los métodos para la producción, purificación y uso de tales composiciones para propósitos terapéuticos e industriales.
MX2009012453A 2007-05-25 2008-05-23 Composiciones de amoniaco-liasa de fenilalanina procariotica y metodos de uso de dichas composiciones. MX2009012453A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/807,227 US7534595B2 (en) 2006-06-12 2007-05-25 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
PCT/US2008/006661 WO2008153776A1 (en) 2007-05-25 2008-05-23 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions

Publications (1)

Publication Number Publication Date
MX2009012453A true MX2009012453A (es) 2010-01-25

Family

ID=39868905

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012453A MX2009012453A (es) 2007-05-25 2008-05-23 Composiciones de amoniaco-liasa de fenilalanina procariotica y metodos de uso de dichas composiciones.

Country Status (30)

Country Link
US (1) US7534595B2 (es)
EP (2) EP2657335A1 (es)
JP (1) JP5670183B2 (es)
KR (2) KR20150038753A (es)
CN (1) CN101842482B (es)
AR (2) AR066716A1 (es)
AU (1) AU2008263190B2 (es)
BR (1) BRPI0811267B8 (es)
CA (1) CA2687450C (es)
CL (1) CL2008001497A1 (es)
CY (2) CY1116894T1 (es)
DK (1) DK2152868T3 (es)
EA (1) EA018443B1 (es)
ES (1) ES2551315T3 (es)
HK (1) HK1135141A1 (es)
HR (1) HRP20151268T1 (es)
HU (2) HUE025784T2 (es)
IL (1) IL202132A (es)
LT (1) LTC2152868I2 (es)
LU (1) LUC00133I2 (es)
MX (1) MX2009012453A (es)
MY (1) MY151413A (es)
NL (1) NL301011I2 (es)
NO (1) NO2019037I1 (es)
PE (1) PE20090315A1 (es)
PL (1) PL2152868T3 (es)
PT (1) PT2152868E (es)
SI (1) SI2152868T1 (es)
TW (1) TWI418633B (es)
WO (1) WO2008153776A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7560263B2 (en) * 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US20110201022A1 (en) * 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
WO2011097335A2 (en) 2010-02-04 2011-08-11 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
CA2880620A1 (en) * 2012-07-27 2014-01-30 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
HUE055899T2 (hu) * 2013-04-18 2022-01-28 Codexis Inc Átszerkesztett fenilalanin-ammónia-liáz polipeptidek
WO2015073587A2 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
EP3125927B1 (en) 2014-04-01 2021-01-27 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
US9605252B2 (en) 2014-04-16 2017-03-28 Codexis, Inc. Engineered tyrosine ammonia lyase
SI3237621T1 (sl) 2014-12-22 2023-11-30 Codexis, Inc. Različice humane alfa-galaktozidaze
TW202340452A (zh) * 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
SG11201811603WA (en) 2016-07-26 2019-02-27 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
EP3508585B1 (en) 2016-08-30 2021-12-15 Mitsubishi Chemical Corporation Method for producing mutant enzyme, and mutant alcohol acyltransferase
CN106497905A (zh) * 2016-12-14 2017-03-15 江南大学 一株鱼腥藻来源的苯丙氨酸脱氨酶的突变体
EP3579867A4 (en) * 2017-02-13 2021-03-10 Codexis, Inc. MANIPULATED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES
CN107653275A (zh) * 2017-10-30 2018-02-02 安徽工程大学 D‑苯丙氨酸的制备方法
CN108004225B (zh) * 2017-12-19 2020-05-08 江南大学 一种成团泛菌来源的苯丙氨酸氨基变位酶的突变体
EP3790627A2 (en) 2018-05-09 2021-03-17 BioMarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
CA3102968A1 (en) * 2018-06-12 2019-12-19 Codexis, Inc. Engineered tyrosine ammonia lyase
JP2021531749A (ja) * 2018-07-12 2021-11-25 コデクシス， インコーポレイテッド 操作されたフェニルアラニンアンモニアリアーゼポリペプチド
AU2019397401A1 (en) 2018-12-14 2021-06-17 Codexis, Inc. Engineered tyrosine ammonia lyase
US11427813B2 (en) 2018-12-20 2022-08-30 Codexis, Inc. Human alpha-galactosidase variants
CN110456056A (zh) * 2019-07-22 2019-11-15 浙江大学 一种新生儿苯丙酮尿症无创筛查试纸的制备方法
US11987823B2 (en) 2019-08-30 2024-05-21 Societe Des Produits Nestle S.A. Engineered lipase variants
US11970722B2 (en) 2019-12-20 2024-04-30 Codexis, Inc. Engineered acid alpha-glucosidase variants
EP4107281A4 (en) * 2020-02-19 2024-08-14 Tufts College PROCESSES FOR ENGINEERING AMINO ACID AMMONIA LYASE ENZYMES AND ENZYMES THUS OBTAINED
AR122409A1 (es) 2020-04-03 2022-09-07 Biomarin Pharm Inc Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
WO2022047264A1 (en) 2020-08-28 2022-03-03 Codexis, Inc. Engineered amylase variants
AU2021334371A1 (en) 2020-08-28 2023-03-09 Codexis, Inc. Engineered protease variants
JP2024519847A (ja) 2021-05-19 2024-05-21 ビオマリン プハルマセウトイカル インコーポレイテッド 原核生物フェニルアラニンアンモニアリアーゼの組成物及び青年対象を治療する方法
WO2023044381A1 (en) * 2021-09-16 2023-03-23 Arcturus Therapeutics, Inc. Compositions and methods for treating phenylketonuria
CN117417925A (zh) * 2022-07-18 2024-01-19 浙江泽科塔生物医药有限公司 Pal变体、包含该pal变体的药物组合物以及用于制备该pal变体的方法
CN116478975B (zh) * 2023-06-16 2023-09-01 苏州优信合生技术有限公司 高活性苯丙氨酸解氨酶突变体及其表达菌株

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
WO1994011535A1 (en) 1992-11-19 1994-05-26 Anticancer, Inc. Use of methioninase as an antitumor agent in anti-methionine chemotherapy
ATE361984T1 (de) 1992-12-04 2007-06-15 Me Medical Enzymes Ag Gentechnologisch hergestellte glutaminase und ihre verwendung in therapie
DK75593D0 (es) 1993-06-25 1993-06-25 Novo Nordisk As
CA2185671A1 (en) * 1994-03-15 1995-09-21 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
DK1568772T3 (da) 1995-09-21 2010-10-18 Genentech Inc Varianter af humant væksthormon
CU22585A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
CA2315944A1 (en) * 1997-12-24 1999-07-08 Diatech Pty. Ltd. Bifunctional molecules
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6403312B1 (en) 1998-10-16 2002-06-11 Xencor Protein design automatic for protein libraries
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
AU772153B2 (en) 1999-02-12 2004-04-08 Molecular Insight Pharmaceuticals, Inc. Matrices for drug delivery and methods for making and using the same
IL150109A0 (en) * 1999-12-09 2002-12-01 Chiron Corp Method for administering a cytokine to the central nervous system and the lymphatic system
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US6939541B2 (en) 2000-04-14 2005-09-06 University Of South Carolina Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase
US6967097B2 (en) 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
US20020076406A1 (en) * 2000-07-25 2002-06-20 Leung Shui-On Multivalent target binding protein
WO2002026028A2 (en) * 2000-09-26 2002-04-04 The Regents Of The University Of California Characterization of phenylalanine ammonia-lyase (pal) gene in wounded lettuce
CN1268641C (zh) * 2000-11-10 2006-08-09 普罗蒂奥制药公司 载脂蛋白类似物
KR20040088538A (ko) 2002-02-26 2004-10-16 이 아이 듀폰 디 네모아 앤드 캄파니 유전 인자의 재조합 방법
AU2003246690B2 (en) * 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
CA2506026A1 (en) 2002-11-14 2004-05-27 The Scripps Research Institute Crystalline form of fatty acid amine hydrolase (faah)
WO2004111089A2 (en) * 2003-06-11 2004-12-23 WYETH A Corporaton of the State of Delaware Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1814984A2 (en) 2004-09-17 2007-08-08 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
CA2614769A1 (en) 2005-03-10 2006-09-21 Verenium Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
WO2008069958A2 (en) 2006-12-01 2008-06-12 The Salk Institute For Biological Studies Substrate switched ammonia lyases and mutases
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

Also Published As

Publication number Publication date
LUC00133I1 (es) 2019-10-16
KR20100024437A (ko) 2010-03-05
EA200970980A1 (ru) 2010-04-30
KR101603796B1 (ko) 2016-03-17
DK2152868T3 (en) 2015-11-16
TWI418633B (zh) 2013-12-11
CN101842482A (zh) 2010-09-22
ES2551315T3 (es) 2015-11-18
EP2657335A1 (en) 2013-10-30
CL2008001497A1 (es) 2009-01-09
HUE025784T2 (en) 2016-05-30
HRP20151268T1 (hr) 2015-12-18
US20080008695A1 (en) 2008-01-10
CY1116894T1 (el) 2017-04-05
AU2008263190B2 (en) 2014-04-17
KR20150038753A (ko) 2015-04-08
CY2019039I2 (el) 2020-05-29
PT2152868E (pt) 2015-11-13
JP2010529835A (ja) 2010-09-02
CN101842482B (zh) 2014-10-22
PL2152868T3 (pl) 2016-01-29
IL202132A0 (en) 2010-06-16
WO2008153776A1 (en) 2008-12-18
LTC2152868I2 (lt) 2020-09-25
US7534595B2 (en) 2009-05-19
AU2008263190A1 (en) 2008-12-18
EA018443B1 (ru) 2013-08-30
BRPI0811267B8 (pt) 2021-05-25
CY2019039I1 (el) 2020-05-29
BRPI0811267A2 (pt) 2014-10-07
PE20090315A1 (es) 2009-03-19
WO2008153776A8 (en) 2009-07-30
JP5670183B2 (ja) 2015-02-18
CA2687450C (en) 2019-03-26
LTPA2019517I1 (lt) 2019-10-25
AR066716A1 (es) 2009-09-09
HK1135141A1 (zh) 2010-05-28
TW200902052A (en) 2009-01-16
EP2152868A1 (en) 2010-02-17
EP2152868B1 (en) 2015-09-02
IL202132A (en) 2017-06-29
HUS1900049I1 (hu) 2019-11-28
LUC00133I2 (es) 2020-07-16
BRPI0811267B1 (pt) 2020-11-10
SI2152868T1 (sl) 2015-12-31
NL301011I1 (nl) 2019-10-16
MY151413A (en) 2014-05-30
NO2019037I1 (no) 2019-10-16
NL301011I2 (nl) 2020-05-13
AR110834A2 (es) 2019-05-08
CA2687450A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
MX2009012453A (es) Composiciones de amoniaco-liasa de fenilalanina procariotica y metodos de uso de dichas composiciones.
MX2009012261A (es) Composiciones de fenilalanina amoniaco-liasa procariota y metodos para tratar cancer utilizando composiciones de las mismas.
CA2782444C (en) Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
HK1131167A1 (zh) 淚液脂質運載蛋白的突變蛋白及其獲得方法
WO2008075371A3 (en) T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
IN2012DN00721A (es)
TW200734311A (en) New compounds
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
MX2009013830A (es) Compuestos antivirales.
MX2009013827A (es) Compuestos antivirales.
ZA200802049B (en) Process for preparing glyceryl carbonate
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
NZ594019A (en) Novel antibacterial agents for the treatment of gram positive infections
TW200720246A (en) Novel process for the preparation of acid chlorides
IN2012DN00639A (es)
NZ733366A (en) Purification of iduronate-2-sulfatase
CA2710814C (en) Bacterial ghost (bg) production process using betapropiolactone (blp) for final inactivation
MX2012002385A (es) Inhibidores macrociclicos de cinasa janus.
MX2007010143A (es) Formas cristalinas de intermedio de linezolid.
MX2010004546A (es) Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina.
MX2007011826A (es) Composiciones farmaceuticas de liberacion controlada de liotironina y metodos para elaborar y utilizar las mismas.
MY159790A (en) Highly bridged peptides from actinomadura namibiensis
RS51259B (sr) Polimorf atorvastatin tert.-butilestra i korišćenje intermediata za dobijanje atorvastatina
IL194353A0 (en) Lysobactin amides
TW200732327A (en) Novel compound

Legal Events

Date Code Title Description
FG Grant or registration